The OncoguardTM Liver solution

Helping make early-stage detection a possibility for more patients at risk of hepatocellular carcinoma

Liver cancer is the fastest growing cause of cancer-related death in the United States.

Beyond 2035, it is expected to surpass colorectal and breast cancer to be the third leading cause of cancer-related death.1

Outcomes for hepatocellular carcinoma (HCC), the most common type of liver cancer, are improved with early-stage detection. However, most cases of HCC are detected in late stages when curative treatments are no longer an option.2,3

Routine surveillance to find early-stage HCC in at-risk patients is the key to giving these patients the chance they each deserve at successful, even curative treatment. However, conventional assessment for HCC is often suboptimal, and far too many patients at risk for HCC do not adhere to guideline-recommended surveillance.2,4

 

63%

A meta-analysis of 32 studies found that using both ultrasound and alpha-fetoprotein (AFP) detected early-stage HCC with only 63% sensitivity, and 47% sensitivity with ultrasound alone.

Undertaking surveillance with AFP alone missed most early-stage disease.5

24%

A meta-analysis assessing patient adherence to HCC surveillance found that surveillance utilization is estimated at 24%.4

GettyImages-1178688517@2x

Meeting the critical needs of at-risk patients

With a comprehensive approach to HCC detection in mind, the OncoguardTM Liver solution was designed with the hope of bringing better outcomes within reach for more patients at risk of HCC.

GettyImages-1220083268@2x

The OncoguardTM Liver solution
helps bridge the gaps in HCC
detection

Asset 6

Enhanced performance to enable early-stage HCC detection versus other guideline-recommended blood tests.

Easy access to testing with a simple, smart, and convenient blood test.

Improved patient adherence to routine testing through a flexible Patient Engagement Program.

healthcare provider

For healthcare providers

The OncoguardTM Liver solution offers a powerful combination of performance, accessibility, and adherence support for a streamlined approach to HCC detection.

Learn about the science, applicability, and logistics of the OncoguardTM Liver solution.

Learn more

content-image-5

For patients

If you have a liver condition and your doctor believes you would benefit from careful watching for early signs of liver cancer, there is a simple blood test that can help provide clear answers.

Learn about the process of getting the OncoguardTM Liver test and what the results could mean for you.

Learn more

References: 1. Rahib L, Wehner MR, Matrisian LM, Nead KT. Estimated projection of US cancer incidence and death to 2040. JAMA Network Open. 2021;4(4):e214708. doi: 10.1001/jamanetworkopen.2021.4708 2. Singal AG, Pillai A, Tiro J. Early detection, curative treatment, and survival rates for hepatocellular carcinoma surveillance in patients with cirrhosis: a meta-analysis. PLoS Med. 2014;11(4):e1001624. doi: 10.1371/journal.pmed.1001624 3. Choi DT, Kum HC, Park S, et al. Hepatocellular carcinoma screening is associated with increased survival of patients with cirrhosis. Clin Gastroenterol Hepatol. 2019;17(5):976-987.e4. doi: 10.1016/j.cgh.2018.10.031 4. Wolf E, Rich NE, Marrero JA, Parikh N, Singal AG. Utilization of hepatocellular carcinoma surveillance in patients with cirrhosis: a systematic review and meta-analysis. [published online ahead of print, 2020 May 8]. Hepatology. 2020;10.1002/hep.31309. doi:10.1002/hep.31309 5. Tzartzeva K, Obi J, Rich NE, et al. Surveillance imaging and alpha fetoprotein for early detection of hepatocellular carcinoma in patients with cirrhosis: a meta-analysis. Gastroenterology. 2018;154(6):1706-1718.e1. doi:10.1053/j.gastro.2018.01.064